Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700
Debt
Debt-to-Equity RatioN/A
Current Ratio10.28
Quick Ratio10.28
Price-To-Earnings
Trailing P/E Ratio-3.01
Forward P/E Ratio-2.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$42 million
Price / Sales4.65
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book1.40
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-39.53%
Return on Assets-35.10%
Miscellaneous
Employees75
Outstanding Shares47,600,000
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.10. The biopharmaceutical company earned $2.32 million during the quarter. View Ardelyx's Earnings History.
What price target have analysts set for ARDX?
5 Wall Street analysts have issued 12-month price targets for Ardelyx's shares. Their predictions range from $12.00 to $17.00. On average, they anticipate Ardelyx's stock price to reach $14.00 in the next year. View Analyst Ratings for Ardelyx.
Are investors shorting Ardelyx?
Ardelyx saw a drop in short interest in the month of May. As of May 31st, there was short interest totalling 580,042 shares, a drop of 55.8% from the May 15th total of 1,311,294 shares. Based on an average trading volume of 1,700,599 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.4% of the shares of the company are sold short. View Ardelyx's Current Options Chain.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), Evolus (EOLS), NuCana (NCNA), Urogen Pharma (URGN), Inflarx (IFRX), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Arcus Biosciences (RCUS), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), CannTrust (CNTTF) and Odonate Therapeutics (ODT).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
- Dr. Reginald Seeto, COO & Exec. VP (Age 46)
- Dr. Paul Korner, Chief Medical Officer & Exec. VP (Age 52)
- Mr. Mark E. Kaufmann MBA, CFO & Treasurer (Age 50)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)
Has Ardelyx been receiving favorable news coverage?
Media stories about ARDX stock have trended somewhat negative this week, according to Accern Sentiment. Accern ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ardelyx earned a news impact score of 0.00 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIPTotal Shares:16,736,044 (27.20%), NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP Total Shares: 16,736,044 (27.20%), BlackRock Inc. (5.47%), Opaleye Management Inc. (2.39%), Dimensional Fund Advisors LP (1.95%) and JPMorgan Chase & Co. (1.72%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell, Nea 15 Gp, Llc and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.
Which institutional investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. Company insiders that have sold Ardelyx company stock in the last year include Forest Baskett and Reginald Seeto. View Insider Buying and Selling for Ardelyx.
Which institutional investors are buying Ardelyx stock?
ARDX stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Opaleye Management Inc., Foresite Capital Management III LLC, Millennium Management LLC, Foresite Capital Management II LLC, Sofinnova Ventures Inc, A.R.T. Advisors LLC and BlackRock Inc.. Company insiders that have bought Ardelyx stock in the last two years include Gordon Ringold and Nea 15 Gp, Llc. View Insider Buying and Selling for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $4.10.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $202.32 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
